AnaptysBio (NASDAQ:ANAB) CFO Sells $705,266.25 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CFO Dennis Mulroy sold 15,725 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $44.85, for a total transaction of $705,266.25. Following the completion of the transaction, the chief financial officer directly owned 9,401 shares in the company, valued at $421,634.85. This trade represents a 62.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

AnaptysBio Stock Performance

NASDAQ ANAB opened at $49.08 on Friday. The company has a market capitalization of $1.36 billion, a PE ratio of -17.40 and a beta of 0.29. AnaptysBio, Inc. has a 52-week low of $12.21 and a 52-week high of $49.90. The company has a 50-day simple moving average of $38.80 and a 200 day simple moving average of $28.96.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $1.58. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The firm had revenue of $76.32 million for the quarter, compared to analysts’ expectations of $15.83 million. As a group, analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its board has approved a stock repurchase plan on Friday, November 21st that permits the company to repurchase $100.00 million in outstanding shares. This repurchase authorization permits the biotechnology company to buy up to 9.6% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s management believes its shares are undervalued.

Analysts Set New Price Targets

ANAB has been the topic of a number of recent research reports. HC Wainwright dropped their price target on AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a research report on Monday, November 24th. Wall Street Zen upgraded AnaptysBio from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, October 8th. Wedbush reiterated an “outperform” rating and set a $50.00 target price on shares of AnaptysBio in a research report on Monday, November 24th. Finally, Truist Financial boosted their price target on shares of AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a research report on Monday, November 10th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.40.

Trending Headlines about AnaptysBio

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Guggenheim sharply raised its price target to $140 from $100, signaling strong analyst confidence in AnaptysBio’s pipeline and upside potential—this is a major bullish catalyst that can attract buyers and momentum investors. Guggenheim target raise
• Positive Sentiment: Recent company fundamentals support a stronger valuation: AnaptysBio reported a large revenue beat and positive quarterly EPS last quarter and the board has authorized a $100M buyback (up to ~9.6% of shares), both of which are supportive of higher share prices and institutional interest. MarketBeat company summary
• Neutral Sentiment: Institutional activity is mixed but constructive: some funds increased positions in Q3 while others adjusted exposure—this shows active interest but not a clear one-way flow. Monitor 13F updates for directional confirmation. Institutional holdings
• Negative Sentiment: CFO Dennis Mulroy sold 15,725 shares (~$705k) in mid‑December, reducing his stake by ~62.6%—a large, recent insider sale that can raise investor concern about near‑term insider sentiment. CFO Form 4
• Negative Sentiment: Executive Eric J. Loumeau completed multiple sales (10,000 and other tranches totaling sizable reductions), cutting his position by ~50–60% in filings—additional insider selling increases short‑term downside risk and can sap sentiment. Insider trades alert Loumeau Form 4
• Negative Sentiment: Barclays lowered its price target to $55 from $70 on Dec. 17, which is a modest negative signal that may temper enthusiasm from other bullish research. Barclays target cut

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. HighMark Wealth Management LLC lifted its holdings in shares of AnaptysBio by 58.2% in the second quarter. HighMark Wealth Management LLC now owns 145,550 shares of the biotechnology company’s stock worth $3,231,000 after buying an additional 53,550 shares in the last quarter. First Light Asset Management LLC increased its holdings in AnaptysBio by 433.3% during the 1st quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock worth $86,139,000 after acquiring an additional 3,764,720 shares during the period. Nuveen LLC bought a new stake in AnaptysBio during the 1st quarter worth approximately $1,041,000. Panagora Asset Management Inc. purchased a new stake in AnaptysBio in the 2nd quarter worth approximately $741,000. Finally, Allianz Asset Management GmbH bought a new position in AnaptysBio in the 2nd quarter valued at $337,000.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.